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Abstract (250 words)
Sofosbuvir-based direct-acting antiviral (DAA)-therapy generally cures chronic hepatitis C (CHC) 
infections, however, the effects on the underlying liver disease and the potential rate of recovery 
are unclear. We aimed to investigate the effects of DAA-therapy on liver inflammation, fibrosis, 
metabolic function and cognitive function and the time course in CHC patients with advanced 
liver disease. Seventy-one CHC patients with advanced liver disease were studied before, during, 
and one year after successful sofosbuvir-based DAA-therapy. Liver inflammation was assessed by 
plasma sCD163 and sMR levels (ELISA), fibrosis by liver stiffness (transient elastography), 
function by galactose elimination capacity (GEC), and cognitive performance by continuous 
reaction time (CRT). 
 During DAA-therapy, we observed a rapid sCD163 decline from baseline to end of treatment 
(EOT) (6.9 vs. 3.8 mg/L, p<0.0001), whereas the change in sMR was more subtle (0.37 vs. 0.30 
mg/L, p<0.0001). Liver stiffness decreased by 20% at end of treatment (17.8 vs. 14.3 kPa, 
p<0.0001), together suggesting rapid resolution of liver inflammation. One-year after treatment, 
liver stiffness decreased by an additional 15% (p<0.0001), suggestive of fibrosis regression. The 
GEC improved at follow-up (all: 1.74 vs. 1.98 mmol/min), mainly at 12-weeks post-treatment, 
both in patients with cirrhosis (n=56) and those with advanced liver fibrosis (n=15) (p<0.001). The 
CRT improved at one-year follow-up (1.86 vs. 2.09, p=0.04). In conclusion, 
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 successful DAA-therapy of CHC proves beneficial in advanced liver disease, with an initial rapid 
resolution of liver inflammation and a subsequent gradual but steady improvement in liver 
fibrosis, metabolic liver function, and reaction time.
Chronic hepatitis C, direct-acting antiviral therapy, fibrosis, portal hypertension, 
metabolic liver function 
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Introduction
In patients with chronic hepatitis C (CHC), the viral infection is a constant trigger of 
inflammation, which subsequently induces formation of fibrosis. With viral clearance, the 
inflammation ceases and thus, the inducer of fibrosis disappears. Patients with CHC are at risk of 
developing cirrhosis and subsequent complications related to portal hypertension and 
hepatocellular carcinoma (HCC) resulting in increased morbidity and mortality 1. These risks are 
consequences of the pathological processes in the liver, i.e. inflammation and progression of 
fibrosis with the subsequent loss of metabolic liver function. 
The all-oral interferon-free direct-acting antiviral (DAA) therapies cure patients with hepatitis C 
virus (HCV) in the majority of cases. Sofosbuvir is a DAA with pan-genotypic effects, which in 
combination with other DAAs or ribavirin provides high sustained virologic response (SVR) rates 
for CHC patients including those with advanced liver disease 2,3. The effect of DAA-treatment on 
the underlying liver disease and associated complications is crucial for the prognosis and future 
management of the patients, but evidence is lacking. Some studies have reported decreased liver 
stiffness after DAA-therapy and viral clearance 4,5, while another reported slight changes in portal 
hypertension 6. Except from HCC study results 7-11, few studies have assessed long-term hepatic 
disease progression 12,13 or mortality after SVR 14, and none have assessed the metabolic liver 
function after DAA-therapy. Thus, it remains unclear in which order the potential changes occur, 
how quickly the changes occur, whether liver inflammation, liver fibrosis, and liver function are 
all affected and how these parameters associate internally after DAA-therapy.
Liver inflammation reflected by macrophage activation may be assessed by measurement of  the 
circulating macrophage activation markers,  soluble (s) CD163 and the soluble mannose receptor 
(sMR), which are elevated in parallel with severity in chronic liver diseases 15-18. Liver fibrosis is 
non-invasively assessed by measurement of liver stiffness using methods such as transient 
elastography (TE) by FibroScan or acoustic radiation force impulse (ARFI) scans. Liver stiffness 
is influenced by a dynamic inflammatory component and structural components, why it provides 
insight into both liver inflammation and fibrosis 19. Liver function may be assessed by the use of 
standard blood parameters; however, this approach provides only limited understanding of the 
complex functions of the liver. Other potential measures of liver function are the galactose 
elimination capacity (GEC) test, which quantifies the metabolism of galactose by galactokinase in 
the hepatocyte cytoplasm, thus reflecting functional liver cell mass 20. Moreover, the continuous 
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reaction time (CRT) reflects cognitive function in patient with severe liver disease and potentially 
the degree of hepatic encephalopathy (HE) 21.
Thus, we aimed to investigate the effect of sofosbuvir-based DAA-therapy on macrophage 
activation, liver stiffness, metabolic liver function, and reaction time in CHC patients with 
advanced liver disease. We hypothesised that sofosbuvir-based DAA-therapy time-dependently 
improves liver inflammation, fibrosis, and function with the majority of the initial effect being on 
inflammation, while the longer-term effects pertain to fibrosis and liver function improvements.
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Materials and Methods
Patients and design
A Danish multi-centre, prospective cohort study was performed among CHC patients undergoing 
sofosbuvir-based DAA-therapy. The patients were included between September 2014 and 
February 2017 in the Central Denmark Region at the Department of Hepatology and 
Gastroenterology and  at the Department of Infectious Diseases at Aarhus University Hospital, 
Aarhus, as well as at the Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, and the 
Department of Medicine, Viborg Regional Hospital, Viborg, where they were referred for 
evaluation and treatment of CHC. Inclusion criteria were CHC with severe liver disease 
(METAVIR F3 or liver stiffness>10 kPa), age ≥18 years, and planned initiation of sofosbuvir-
based DAA-therapy. A diagnosis of cirrhosis was based on either liver biopsy, or a combination of 
liver stiffness>15 kPa 22 with radiological, clinical, and/or biochemical signs of liver cirrhosis. The 
cirrhosis patients were routinely screened for HCC with biannual ultrasound scans. Exclusion 
criteria were co-infection with HBV or HIV and excessive alcohol intake within the last 6 months 
preceding treatment initiation. In total, 143 patients with CHC were screened for participation in 
the study and 71 (50%) patients were included 13 treatment-experienced; 9 of these had failed 
interferon-based therapies and 4 DAA-treatments as well. The reasons for screening failure of the 
72 patients who were not included in the study are shown in Supplementary figure 1. Interim 
results on macrophage activation and liver stiffness from the first 38 patients have previously been 
reported in another study from our group 23. The study was performed in accordance with the 
Helsinki declaration and the ethical review board in the Central Denmark Region approved the 
study (1-10-72-199-14). All included patients signed informed consent forms. 
DAA-therapy
The decisions on whether to initiate treatment and the treatment regimen were made in consensus 
by a team of experienced clinicians according to national guidelines at the time of the study. The 
treatment regimens included sofosbuvir and potentially a second DAA, i.e. daclatasvir, simeprevir, 
or ledipasvir, depending on the genotype. Some regimens also included weight-based ribavirin 
with potential dose reduction at the occurrence of anaemia. For treatment details see 
Supplementary table 1. Most patients were treated for 12 weeks, however extension of treatment 
to 16 or 24 weeks was made at the discretion of the responsible physicians. Viral load 
measurements were obtained at all visits and determined using qPCR assays with a lower A
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detection limit of 9 IU/mL and a lower quantifiable limit of 15 IU/mL. SVR was defined as 
undetectable HCV-RNA at 12 weeks (SVR12) and one year (SVR52) after treatment cessation. 
Adverse events (AE) and serious adverse events (SAE) were recorded and SAEs were reported to 
relevant authorities. In total, 73% of the patients experienced adverse events during treatment. In 
general, these were mild and mainly present during the first treatment week (Supplementary table 
2).
Biochemical methods
Blood sampling was performed before treatment, at week 1, 2, 4, and 8 during treatment, at the 
end of treatment (EOT), and 12 weeks and one year after treatment (Supplementary figure 1). If 
the treatment period was extended, blood sampling was performed every 4 weeks during the 
extension. Standard biochemical parameters were analysed using validated assays at the respective 
sites. The Child-Pugh score was calculated at each visit using bilirubin, albumin and international 
normalized ratio (INR), as well as the presence of HE and ascites. The model of end-stage liver 
disease (MELD) score was calculated using bilirubin, creatinine, and INR. The quantification of 
sCD163 and sMR was performed by use of an in-house sandwich enzyme-linked immunosorbent 
assays (ELISA) using a BEP-2000 ELISA-analyser (Dade Behring, Siemens, Erlangen, Germany) 
as previously described 16,24. sCD163 and sMR are stable at -80°C for long periods of time and 
resistant to repeated freezing and thawing. Control samples and standards were included in each 
run.
Measures of liver stiffness and portal hypertension
Liver stiffness was assessed using transient elastography (FibroScan, Echosens, Paris, France) or 
ARFI-scans (Siemens, Erlangen, Germany). The measurements were performed by trained 
doctors, nurses or bio technicians before initiation of treatment, at EOT, at 12 weeks and one-year 
post-treatment. To ensure the validity of the FibroScan measurements, at least 60% valid 
measurements in a complete series (10 approved measurements), had to be achieved. Additionally, 
the interquartile range (IQR) had to be below 25% of the median for the result to be approved as 
recommend in the Central Denmark Region. The ARFI-elastography is integrated into a 
conventional ultrasound device and was performed as previously described 25. The liver stiffness 
data are reported separately for the FibroScan and the ARFI-scans and as a percentage, where all 
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baseline values are set as 100% and the subsequent values are reported as percentage of the 
baseline value.
In patients with a clinical indication,  liver vein catheterizations were performed to evaluate the 
degree of portal hypertension using an established method as previously described, thus estimating 
the hepatic venous pressure gradient (HVPG) 26. 
Metabolic liver function by the galactose eliminations capacity (GEC) test
Galactose is almost exclusively metabolized in the liver, and the GEC evaluates the ability of the 
liver to eliminate galactose from the bloodstream, thus, it may be used as a quantitative measure of 
the metabolic capacity of the liver 27. Briefly explained, a galactose solution is injected 
intravenously over 5 minutes (1 ml/kg body weight of a 500 mg/mL galactose solution), 
arterialized capillary blood is sampled 8 times every 5 minutes from 20 minutes after the injection 
to measure the blood concentration of galactose, and urine is collected for 4 hours to measure 
urinary excretion of galactose. The GEC is calculated from the injected amount subtracting the 
excreted amount and from the straight line connecting the observations of the blood galactose 
concentration against time 28. For each patient, GEC results are presented as millimoles galactose 
cleared per minute (mmol/min) and a percentage of an expected normal value based on weight 
(%).
Continuous reaction time (CRT)
The CRT evaluates cerebral function by testing the ability to react to sounds for a longer period of 
time. The test is performed using a laptop, dedicated software (EKHO, Bitmatic, Aarhus, 
Denmark), headphones, and a trigger button as previously described 21. Results are reported as the 
variation coefficient of the reaction times delivered during the test called the CRT index, which 
reflects reaction time stability. A CRT index below 1.9 is considered pathological, and may reflect 
minimal HE in liver disease 21.
Statistical methods
Changes over time were evaluated with univariate or multivariate repeated measurements analysis 
of variance (ANOVA) using mixed models. Equality or inequality of standard deviations and 
correlations in the models were considered as appropriate. Model validation was performed by 
comparing observed and expected within subject standard deviations and correlations by A
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inspecting QQ-plots. Student’s t-tests were used to study differences between groups, and one-
way ANOVAs were used for the comparisons of multiple groups. Log-transformation was 
performed when appropriate. For the non-normally distributed data, Kruskal-Wallis and Mann-
Whitney tests were used. The relationships between continuous variables were analysed using 
Spearman’s rank correlation. Binary data were analysed using Chi2 or Fisher’s exact depending on 
sample size. All data are reported as medians with 95% confidence intervals (CI) or proportions 
unless otherwise stated. P-values <0.05 are considered statistically significant. The data analyses 
were performed using STATA v. 14.0 (Stata Corp LP, College Station, TX, USA).
Results
Baseline patient characteristics
In total, 71 patients with CHC were included in the study. Baseline patient characteristics are 
shown in Table 1. All the patients, both treatment-naïve and -experienced, achieved SVR12 and 
SVR52 except for one treatment-experienced patient initially infected with genotype 1, but re-
infected with a genotype 3-strain 12 weeks after treatment. Overall, this corresponds to an SVR-
rate of 98.6%.  At baseline, all patients had advanced liver disease with inflammation 
corresponding to elevated alanine aminotransferase (ALT) levels [77 IU/L (95% CI:66-87)] and 
elevation of the sCD163 level to nearly twice the upper normal limit [6.9 mg/L (6.0-7.8), reference 
interval: 0.7-3.9 mg/L]. For sMR, the baseline level was 0.37 mg/L (0.34-0.42) with a reference 
interval of 0.10-0.43 mg/L. The macrophage activation markers correlated with each other and a 
number of biochemical parameters, most notably albumin, alkaline phosphatase, bilirubin and -
fetoprotein (Supplementary table 3).
Of the 71 included patients, 15 (21%) patients had advanced liver fibrosis and 56 (79%) patients 
had cirrhosis; 49 with Child-Pugh A cirrhosis and 7 with Child-Pugh B cirrhosis. The median liver 
stiffness was 22 kPa (18-31) using FibroScan (n=43) and 1.9 m/s (1.8-2.0) on the ARFI-scans 
(n=28). Liver stiffness was highest in the Child-Pugh B patients [40.0 kPa (25.5-75), 2.6 m/s (1.9-
3.3)]. The median MELD-score was 8.5 (7.5-8.5) for the entire group and higher in the Child-
Pugh B patients [11.7 (8.9-14.0)]. The GEC was performed in 54 (76%) patients before treatment 
with a median value of 1.74 (1.60-1.88), corresponding to 59% (56-64) of normal. The patients 
with cirrhosis had lower metabolic liver function by GEC at baseline compared with the patients 
who had advanced liver fibrosis (57% vs. 76%, p=0.01). At baseline, 44 (62%) patients had a CRT 
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performed with a mean CRT index of 1.86 (1.66-2.06), which is below the normal limit of 1.9 
suggestive of minimal HE.
Effects of DAA-therapy on liver inflammation and fibrosis
ALT rapidly improved with a 50% decrease during the first week of DAA-therapy and 
normalization by EOT (Table 2). The levels of sCD163 and sMR decreased by 44% and 19%, 
respectively, from baseline to EOT (p<0.0001), suggesting rapid resolution of liver inflammation 
(Figure 1). There was a significant increase (17%) in sCD163 from EOT to 12-weeks post-
treatment followed by a similar significant decrease (14%) at one-year post-treatment (p<0.0001). 
There were no changes in sMR at EOT compared with the levels at follow-up (p>0.3, both). The 
patients with no history of excessive alcohol consumption had a significantly more pronounced 
decrease in sCD163 during the study period (p<0.001); this was not the case for sMR (p=0.19). 
Over the entire study period, there was a significant decrease in liver stiffness as the relative 
change from baseline (p<0.001). A large part of the decrease occurred before EOT; thus, the liver 
stiffness decreased by 14% at EOT (8-20, p<0.0001) (Figure 2). From EOT to one-year post-
treatment, liver stiffness decreased by a further 11% (5-18) and by 6% (1-13%) between 12-weeks 
and one-year post-treatment. Thus, in the patients with advanced fibrosis, the liver stiffness 
reached a final median value at one-year post-treatment of 5.5 kPa (4.1-8.6) on FibroScans and 
1.39 m/s (1.22-1.70) on the ARFI-scans. The cirrhosis patients ended up at a median liver stiffness 
of 13.5 kPa/1.81 m/s (10.2-20.5 kPa/ 1.70-2.10 m/s). For the Child-Pugh B patients the median 
liver stiffness ended at 39.8 kPa/ 3.16 m/s (14.8-72 / 2.37-3.95 m/s) at one-year post-treatment 
follow-up. The decrease in liver stiffness was accompanied by a similar significant increase in 
albumin from EOT to one-year post-treatment (35.7 (34.5-36.8) vs. 37.5 (36.2-38.7), p<0.001), 
and was complemented by an overall half point decrease in mean MELD score (8.6 (8.0-9.2) vs. 
8.1 (7.5-8.7), p=0.03).
Effects of DAA-therapy on liver function
Thirty-six (51%) patients completed a follow-up GEC and among those the outcome of the test 
improved significantly over the entire study period (p<0.001) (Figure 3). The increase was 
significant from baseline compared with follow-up both at 12-weeks and one-year post-treatment 
(p=0.001), however with no significant change between 12-weeks and one-year post-treatment A
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(p=0.71). At one-year post-treatment, the mean GEC for the entire cohort was improved to 1.98 
mmol/min (1.83-2.14), which corresponded to 66% (61-72) of normal (n=26) compared with 59% 
(56-64) at baseline. The difference in metabolic liver function between cirrhosis patients and 
advanced fibrosis patients was sustained during the entire study period with the cirrhosis patients 
ending at 1.95 mmol/min (1.80-2.10) (64%) and the patients with advanced fibrosis at 2.24 
mmol/min (1.88-2.60) (82%) (Figure 3).
At 12-weeks post-treatment, 36 (51%) patients completed a follow-up CRT providing a mean 
CRT index of 2.03 (1.82-2.24). One-year after treatment cessation, the mean CRT index was 2.09 
(1.87-2.32) (n=29), which corresponded to an increase of 0.24 (0.01-0.47) in the CRT index from 
baseline to one-year after treatment (p=0.04) (Figure 4).
Correlations between liver inflammation, fibrosis, and function before and after DAA-therapy
The levels of sCD163 and sMR were more than 40% higher in the 56 patients with cirrhosis at all 
times points in comparison with the 15 patients with advanced liver fibrosis (50% (14-98%) and 
40% (11-76%), respectively (p<0.01). Five cirrhosis patients (7%) developed de novo HCC and 
two patients recurrent HCC during follow-up (3%). In a mixed model, the dynamics of sCD163 
were different over time in the patients who developed HCC compared with the patients who did 
not (p=0.02), with tendencies of increased levels at EOT and during follow-up in HCC patients 
(sCD163: p<0.16, sMR: p<0.07). The levels of the macrophage activation markers correlated with 
liver stiffness at baseline (r>0.39, p<0.05) (Supplementary table 3), and at follow-up, though only 
when using the FibroScans (r>0.48, p<0.03). At baseline, we found inverse correlations between 
the macrophage activation markers and the GEC (r=-0.41/-0.47, p<0.003) (Supplementary table 3) 
but no association at follow-up (p>0.08). The levels of sCD163 and sMR were not significantly 
associated with CRT at baseline (Supplementary table 3) or during follow-up, except for a 
negative correlation between sMR and the CRT 12-weeks after treatment (r=-0.43, p=0.02). The 
changes in sCD163 or sMR did not correlate with the changes in liver stiffness, GEC, or CRT 
neither during or after treatment (p>0.07). 
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Discussion
This study demonstrates the time-dependent liver-related effects of successful sofosbuvir-based 
DAA-therapy in patients with CHC and advanced liver disease, the majority with cirrhosis. The 
main effect on liver inflammation is rapid and instigates early after therapy initiation. The long-
term effects consist of diminished liver stiffness and improved metabolic liver function and 
reaction time. Interestingly, the effects on liver function occur as early as 12 weeks after treatment 
and are sustained at one-year follow-up.
The major strength of the study is the prospective design and comprehensive work-up of the 
patients. We included all consecutively consenting patients with advanced liver disease or 
cirrhosis planned to initiate sofosbuvir-based DAA-therapy at hospitals in the Central Denmark 
Region over a two and a half-year period, hence providing generalizable results from a real-life 
cohort. The limitations of the study, though, pertain to the lack of histological verification of liver 
inflammation and fibrosis. However, we and others have previously shown very good associations 
between the macrophage activation markers and liver inflammation 15,23 as well as between liver 
stiffness and fibrosis, even after SVR 29,30. Another limitation is that not all patients underwent 
transient elastography by the same method being either the FibroScan or the ARFI-method, 
however as the combined and separate associations seem similar, we consider the results valid. 
However, it is interesting that the magnitude of the changes seem larger for the FibroScan results 
compared with the ARFI-scan results and it might be suggested that the outcome of FibroScan 
may be more affected by the presence of liver inflammation. 
As part of the inflammatory processes in the liver, CD163 and the mannose receptor (MR) are 
released from the surface of activated macrophages in the liver and are found in the blood as 
circulating sCD163 and sMR 16,24. The receptors are differentially expressed on different 
macrophage subtypes 31,32. In addition, CD163 is a lineage specific monocyte/macrophage marker, 
while the MR is also detected on the surface of dendritic and endothelial cells. The CD163 
receptor is known to specifically bind hemoglobin-haptoglobin complexes, whereas the MR binds 
a variety of endogenous and exogenous substances, why their mechanisms of shedding are 
probably different 33,34. This may explain the difference in the degree of elevation between 
sCD163 and sMR in CHC patients, as well as the different dynamics of the two markers during 
and after DAA-treatment.
The observations of rapidly improved ALT and sCD163 values combined with a decrease in liver 
stiffness within the period of DAA-therapy suggest prompt resolution of liver inflammation in A
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parallel with clearance of the hepatitis C virus. This is supported by several studies with similar 
results regarding inflammatory mediators, sCD163 and liver stiffness during DAA-therapy 35-37.
Next, we examined the long-term effects of DAA-therapy on liver fibrosis during one-year follow-
up after treatment and found a continued decrease in liver stiffness. Whereas ALT and sCD163 
levels had plateaued already at EOT, liver stiffness continued to decrease possibly because of 
subsequent regression of liver fibrosis. Fibrosis regression has been investigated extensively in 
chronic hepatitis B patients after nucleoside treatment and in CHC patients after interferon 
treatments with results pointing towards a potential for regression or even resolution at longer 
follow-up 38,39. A similar effect of DAA-therapies is becoming evident and fibrosis regression may 
also lead to diminished portal hypertension with discrete improvements in portal pressure after 
DAA-therapy 6,30. In a small number of patients (n=4), we observed a trend towards reduced portal 
hypertension. This was accompanied by improved platelet count, albumin levels and MELD 
scores, suggestive of improvement of liver disease severity related to diminished fibrosis.
The improvements in liver inflammation and fibrosis are likely the reason for the augmented 
metabolic liver function, as others have shown that the GEC is associated with liver inflammation, 
disease severity, and prognosis in cirrhosis patients 28,40,41. Thus, we highlight the improved 
metabolic liver function as an important clinical finding.
Many cirrhosis patients have minimal HE with decreased quality of life and increased risk of 
developing clinically manifest HE 42. We assessed the cognitive function of our patients by 
quantifying reaction time stability using the CRT. At baseline, the patients indeed had a mean 
CRT index within the pathological limits suggestive of minimal HE. However, with DAA-therapy, 
this improved and the mean level ended above the cut-off level. The change of 0.24 is between the 
values of what is observed with the usual recommended anti-HE medication and placebo in 
cirrhosis patients 43, and may potentially be attributed to reduced cerebral inflammation and 
improved neural health 44,45. The improvements in GEC and reaction time is promising and calls 
for further studies with longer follow-up to assess the potential improved prognosis for patients 
with CHC and advanced liver disease or cirrhosis undergoing DAA-treatment.
Even though the overall results are generally positive, several patients deteriorated after DAA-
therapy. One cirrhosis patient decompensated with acute variceal bleeding, five cirrhosis patients 
developed de novo HCC and two patients recurrent HCC. The sCD163 levels correlated with 
alpha-fetoprotein and the sCD163 dynamics over the entire study period was different between 
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patients with HCC compared with patients without HCC, which may suggest that sCD163 may be 
valuable in the surveillance of patients after SVR.
Taken together, this study shows that with successful DAA-therapy a rapid resolution of liver 
inflammation occurs followed by more subtle changes in liver fibrosis. Further, this study is the 
first to show the beneficial effects of DAA-therapy on metabolic liver function and reaction time 
in patients with CHC and advanced liver disease, thus, suggesting a possibility for improved 
outcome with perspectives such as decreased morbidity and mortality.
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Tables
Table 1. Baseline patient characteristics.
Number (%) Median (95% CI)
Age (Years) 55 (53-58)
Gender
Male 45 (63)
Female 26 (37)
BMI (kg/m2) 25 (24-27)
Diabetes 11 (15)
Alcohol
No alcohol † 31 (44)
Occasional 1 (1)
Previous over intake 39 (55)
Genotype
1a 14 (20)
1b 3 (4)
2 2 (3)
2b 1 (1)
3 36 (51)
3a 14 (20)
6e 1 (1)
Ethnicity
Caucasian 67 (94)
Other 4 (6)
MELD score 8.5 (7.5-8.5)
Liver stiffness
Fibroscan (kPa) (n=43) 22 (18-31)
ARFI-scan (m/s) (n=28) 1.9 (1.8-2.0)
Cirrhosis 56 (79)
Child-Pugh Score 5 (5-6)
Child-Pugh ClassA
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A 49 (69)
B 7 (10)
Previous HCC 4 (6)
Alpha-fetoprotein (x10^3 IU/L) 5 (4-5)
Gastroscopy 54 (76)
No varices 40 (56)
Grade 1 varices 13 (18)
Grade 2 varices 1 (1)
PHG 21 (30)
CI, confidence interval; BMI, body mass index; MELD, model of end-stage liver disease; HCC, 
hepatocellular carcinoma; PHG, portal hypertensive gastropathy. † No history of excessive alcohol 
consumption
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Table 2. Biochemical changes with DAA-therapy.
Baseline Week 1 End of treatment One-year
ALT (IU/L) 77 (66-87) 43 (36-49) * 24 (21-27) * 24 (21-28) *
Bilirubin (umol/L) 10 (9-11) 17.1 (14.7-19.5) * 11 (10-13) * 9 (7-10) *
Alkaline phosphatase (IU/L) 98 (88-107) 92 (83-101) * 84 (77-92) * 91 (82-100) *
Albumin (g/L) 35.4 (34.2-36.5) 35.3 (34.1-36.5) 35.7 (34.5-36.8) 37.5 (36.2-38.7) *
Creatinine (umol/L) 70 (65-74) 71 (66-76) 72 (67-76) 70 (65-74)
Leukocytes (x10^9/L) 6.0 (5.5-6.5) 6.7 (6.1-7.3) * 5.9 (5.4-6.4) 6.6 (6.0-7.1) *
Haemoglobin (mmol/L) 8.8 (8.5-9.0) 8.5 (8.2.8.8) * 7.4 (7.2-7.6) * 8.8 (8.5-9.1)
Platelets (x10^9/L) 137 (123-152) 148 (132-164) * 170 (151-188) * 161 (143-178) *
INR 1.2 (1-1-1.2) 1.2 (1.1-1.2) 1.2 (1.1-1.2) 1.1 (1.1-1.2)
Virus load (x10^3 IU/mL) 805 (398-1200) 0.3 (0.1-0.4) * 0* 0*
Alpha-foetoprotein 4.8 (3.7-5.8) - 3.2 (2.5-3.9)* 2.7 (2.1-3.4)*
Data are reported as medians with (95% CI). *p<0.05 compared with the baseline values.
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Figure legends
Figure 1. The dynamics of the macrophage activation markers, sCD163 and sMR at baseline, at 
designated weeks during treatment (1, 2, 4, 8), at the end of treatment (EOT) and after treatment 
(12-weeks and one-year post-treatment cessation). The dots represents medians with 95% CI 
based on a mixed model.
 
Figure 2. Liver stiffness in the patients with chronic hepatitis C at baseline, at the end of treatment 
(EOT), at 12-weeks post-treatment and one-year post-treatment, reported as relative changes from 
baseline. The patients are divided into the following groups: patients with advanced fibrosis 
(n=15), Child-Pugh A cirrhosis patients (n=49) and Child-Pugh B patients (n=7).
 
Figure 3. Galactose elimination capacity (GEC) reported in percentage of normal values in the 
patients with chronic hepatitis C at baseline, at 12-weeks post-treatment and one-year post-
treatment. The dots represents means with 95% CI based on a mixed model.
Figure 4. The continuous reaction time (CRT) index in the patients with chronic hepatitis C at 
baseline, and at 12-weeks and one-year after treatment cessation. The dots represents means with 
95% CI based on a mixed model. The dashed line represents the lower limit of the normal interval.
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